A Contract Manufacturing Organization (CMO) is a company that specializes in providing services such as drug manufacturing to other businesses within the biopharmaceutical sector. Biotechnology contract manufacturing plays a crucial role in the biopharmaceutical industry by enabling companies to focus on research, development, and commercialization while entrusting specialized partners with efficient and compliant manufacturing processes. This collaborative approach facilitates the introduction of innovative biotech products to the market, benefiting both biotech firms and patients seeking advanced therapies.
Global Biotechnology Contract Manufacturing Market was valued US$ 16.5 Bn in 2022 and is expected to reach ~US$ 36.5 Bn by 2032, growing at a CAGR of 8.3% during the forecast period 2023-2032.
Several factors contribute to the growth of the biotechnology contract manufacturing market, including the increasing demand for biologics and biosimilars, the growing outsourcing of biologics manufacturing by biopharmaceutical companies, a heightened focus on personalized medicine, expanding partnerships between pharmaceutical companies and biologics contract manufacturers, and technological advancements in the manufacturing sector. Furthermore, the market is expected to experience growth due to rising demand for cell and gene therapies and the expanding biologics production capabilities of CMOs. However, large corporations view outsourcing as risky due to the loss of strategic control and limited management oversight, leading them to prefer keeping their manufacturing processes in-house. This could pose certain challenges related to the growth of biotechnology contract manufacturing.
COVID -19 Impact on Biotechnology Contract Manufacturing Market
The COVID-19 pandemic has had a notable impact on the Biotechnology Contract Manufacturing Market. The pandemic disrupted global supply chains and caused significant shifts in healthcare priorities and manufacturing capabilities, which in turn affected the contract manufacturing landscape in biotechnology. The pandemic disrupted supply chains worldwide, leading to delays in the availability of raw materials, equipment, and other resources needed for biotechnology contract manufacturing. This disrupted the production and distribution of biopharmaceuticals, impacting both ongoing and planned manufacturing contracts.
During the pandemic, there was a shift in priorities within the healthcare sector, with a heightened focus on the development and manufacturing of vaccines, treatments, and diagnostics for COVID-19. This shift diverted resources and attention away from other biopharmaceutical products, potentially affecting contract manufacturing projects. The need for social distancing and lockdown measures led to challenges in managing and overseeing contract manufacturing processes.
On the positive side, the biotechnology contract manufacturing sector played a crucial role in scaling up the production of COVID-19 vaccines. Several contract manufacturing organizations (CMOs) were involved in the production of vaccines, contributing to the global vaccination efforts. The pandemic highlighted the importance of resilience and adaptability in the biopharmaceutical industry. CMOs that could quickly pivot to meet the demand for COVID-19-related products demonstrated their flexibility and ability to respond to unexpected challenges.
While the immediate impact of the pandemic disrupted supply chains and manufacturing timelines, the long-term impact on the biotechnology contract manufacturing market is still evolving. The experience of the pandemic has prompted many companies to re-evaluate their supply chain strategies and consider redundancies and contingency plans to mitigate future disruptions.
Factors Driving the Biotechnology Contract Manufacturing Market
Drivers
Increasing demand for biologics
The biologics contract manufacturing market is experiencing remarkable growth due to several key factors, including the expanding biologics pipeline, growing manufacturing complexities, and a strategic shift by companies towards core activities. Currently, many pharmaceutical and biotechnology firms are outsourcing a wide range of services, spanning early-stage drug development to large-scale manufacturing. Outsourcing has become essential to expedite research and development, accelerate market entry, gain access to cutting-edge technologies, leverage regulatory expertise, and mitigate risks, all while maintaining cost competitiveness.
The intricate nature of biologics development and production, coupled with increasingly stringent quality standards, has motivated drug manufacturers to favor the services of contract manufacturing organizations (CMOs). Furthermore, numerous companies are embracing the services of CMOs to expedite the development process and reduce production expenses. For example, Sanofi has chosen to outsource the manufacturing of its biologics pipeline to Boehringer Ingelheim. In addition, TaiMed Biologics relies on CMO WuXi PharmaTech for the manufacturing of Ibalizumab, an FDA-designated orphan drug. Furthermore, in 2021, Samsung Biologics expanded its collaboration with AstraZeneca, which began in 2020. This partnership encompasses the production of a drug substance, including AstraZeneca's COVID-19 long-acting antibody combination, with manufacturing of a cancer immunotherapy product commencing in 2022.
Opportunity
Rising demand for cell therapies and gene therapies
Cell and gene therapies, with their exceptional specificity and potential to target previously untreated medical conditions that do not respond to small molecule drugs and other biologics, represent a promising avenue for addressing unmet healthcare needs. This therapeutic potential has spurred the efforts of numerous pharmaceutical companies to invest in the development and commercialization of these therapies, resulting in a substantial increase in demand for services related to their research and production.
As of April 2022, the US FDA has granted approval to more than 20 cell and gene therapies, highlighting the significant growth and progress in this field. The expanding pipeline of candidates for cell and gene therapies, their progression through various phases of clinical development, and the intricate nature of their manufacturing processes have all contributed to a heightened need for manufacturing facilities capable of offering services for these therapies. This ongoing trend is anticipated to create valuable growth opportunities for contract manufacturing services within the cell and gene therapy sector.
Challenge
Strict Regulations
FDA regulations mandate strict adherence to guidelines set by the relevant regulatory authority. Contract manufacturing organizations (CMOs) are tasked with obtaining regulatory approvals for the same molecule from various regions, customizing their submissions to meet specific client needs. The complexity of this process is compounded by variations in regulations and submission requirements across different countries. Errors in this intricate endeavour can present substantial hurdles for innovators seeking entry into regulated markets. The challenge is further exacerbated by the necessity to align manufacturing practices with the latest regulatory changes. Consequently, CMOs face the formidable challenge of consistently meeting evolving standards across diverse regions and countries.
Biotechnology Contract Manufacturing Market Segmentation
By Service
The global biotechnology contract manufacturing market comprise major segments such as manufacturing, formulation and fill-finish, packaging and labelling and other services.
In 2022, the manufacturing segment emerged as the dominant player in the worldwide biotechnology contract manufacturing market. Biopharmaceutical manufacturing encompasses various stages, including upstream and downstream manufacturing. Given the intricate nature of biologics production, biopharmaceutical companies continually grapple with the design, optimization, and implementation of advanced protocols and procedures to ensure product purity. This ongoing challenge drives biologic manufacturers to seek external assistance for production, allowing them to meet production objectives while remaining at the forefront of evolving industry trends and technologies. This underscores the growing trend of outsourcing manufacturing services.
By Type
The global biotechnology contract manufacturing market comprises major segments such as Biologic Drug Substance, Manufacturing and Biologic Drug Product Manufacturing.
In 2022, the biologic drug substance manufacturing sector claimed the majority share in the global biotechnology contract manufacturing market. This substantial share is a result of heightened research activities aimed at developing innovative therapies for addressing chronic diseases. With many patented drugs nearing their expiration, there is a growing need for newer, targeted therapies such as monoclonal antibodies, cell therapies, and gene therapies. The production of these intricate drug substances necessitates advanced equipment and manufacturing technologies. As a result, innovator companies are increasingly inclined to contract out the manufacturing of these biological drug substances, thus contributing to market expansion.
By Scale of Operation
The segmentation of the biotechnology contract manufacturing market into commercial operations and clinical operations distinguishes between two significant stages in the production and development of biotechnological products. Commercial operations in biotechnology contract manufacturing pertain to the manufacturing, production, and scale-up of biopharmaceuticals for widespread distribution and commercial sale. This stage involves mass production for the market. Manufacturers in this segment adhere to stringent regulatory standards and good manufacturing practices (GMP) to ensure product quality, safety, and consistency. Meeting these requirements is crucial for obtaining regulatory approvals and commercialization. The focus of this segment is on meeting market demands for biopharmaceuticals, vaccines, and other biotechnological products. Manufacturers in this segment aim for large-scale production efficiency, cost-effectiveness, and timely delivery to supply the market. Clinical operations in biotechnology contract manufacturing involve smaller-scale production primarily for research, development, and clinical trials. This phase precedes commercial production and focuses on product development and testing. The focus of this segment is to support biotech companies in their R&D efforts, providing the necessary quantities of products for clinical trials and aiding in the process of gaining regulatory approval by ensuring that the products meet safety and efficacy standards.
By Source
The source segmentation of the biotechnology contract manufacturing market include mammalian and non-mammalian expression systems. These are the different methods or platforms used in biopharmaceutical production to create and express proteins or biologically active compounds. Mammalian expression systems use cells derived from mammals, such as Chinese hamster ovary (CHO) cells or human cells, to produce proteins. These cells are capable of post-translational modifications, ensuring correct folding and assembly of complex proteins. Non-mammalian expression systems use organisms such as bacteria (like E. coli), yeast, insect cells, or plant cells to produce proteins or biologically active compounds. These systems are often simpler and cost-effective.
By Molecule
The segmentation of the biotechnology contract manufacturing market into various product categories delineates the specific types of biopharmaceuticals and biotechnological products that are produced under contract manufacturing services. Each category represents a distinct class of products with unique characteristics and manufacturing requirements. Monoclonal Antibodies are laboratory-produced antibodies designed to target specific proteins or cells, often used in the treatment of various diseases, including cancers, autoimmune disorders, and infectious diseases. Cell therapy involves the use of cells, often a patient's own cells, to treat diseases. Gene therapy aims to modify or introduce genetic material into cells to correct genetic disorders. Antibody-Drug Conjugates (ADCs) are a type of targeted therapy that uses monoclonal antibodies to deliver drugs specifically to cancer cells. Vaccines are biopharmaceuticals that help prevent infectious diseases by stimulating the immune system to recognize and combat pathogens. Therapeutic Peptides & Proteins involves smaller protein-based therapies such as insulin, growth hormones, and various other peptides used in treating a range of conditions. Other category involves category encompasses a range of other biopharmaceutical products not covered in the previously mentioned segments. It could include various innovative therapies, novel molecules, or emerging biotechnological products not yet standardized into specific categories.
By Therapeutic Areas
The segmentation of the biotechnology contract manufacturing market into therapeutic areas signifies the specific focus or application of the biopharmaceutical products manufactured through contract services. Each segment corresponds to a distinct medical field or category of diseases, dictating the types of treatments and medications being developed and produced. Oncology segment encompasses the development and manufacturing of biopharmaceuticals related to cancer treatment. It includes therapies such as monoclonal antibodies, chemotherapies, targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs) designed to combat various forms of cancer. Autoimmune diseases involve the development of medications that regulate or suppress the immune system to treat conditions like rheumatoid arthritis, multiple sclerosis, lupus, and other autoimmune disorders. Cardiovascular Diseases segment focuses on medications and therapies designed to treat conditions affecting the heart and blood vessels, including drugs for hypertension, heart failure, coronary artery disease, and other cardiovascular disorders.
Metabolic Diseases category includes the development of treatments for metabolic disorders such as diabetes, obesity, and metabolic syndrome. It involves medications like insulin, glucagon-like peptide-1 (GLP-1) agonists, and other therapies targeting metabolic imbalances. Infectious Diseases area involves the development of vaccines, antiviral medications, and antibiotics to prevent and treat various infectious diseases caused by bacteria, viruses, fungi, and other pathogens. Neurology segment encompasses medications and therapies for conditions affecting the nervous system, including neurodegenerative diseases like Alzheimer's, Parkinson's, epilepsy, and other neurological disorders. Other Therapeutic Areas category may include emerging therapeutic areas, niche markets, or other medical conditions that do not fit explicitly within the delineated segments but are essential in the broader spectrum of healthcare and treatment.
By Regions
By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America.
The Asia Pacific region presents a highly promising growth opportunity for the biotechnology contract manufacturing market. This can be attributed to several factors, including the rising investments in pharmaceutical research and development (R&D), the increasing trend of outsourcing manufacturing services, and growing government initiatives aimed at advancing healthcare research. One significant driver fuelling market growth in the Asia Pacific region is the substantial investment in healthcare infrastructure and R&D endeavours. Additionally, the increasing prevalence of chronic diseases and the region's large population are driving the demand for innovative therapies, thereby supporting the need for biologic drugs and their outsourced manufacturing. Furthermore, the favourable regulatory guidelines for drug approval in the region are expected to further propel market growth. The growth of the biotechnology contract manufacturing market in the Asia Pacific region can be credited to several factors, including the region's robust pharmaceutical and biotech sectors, the well-established pharmaceutical industry infrastructure, a growing demand for biologics and biosimilars, and the increasing trend of outsourcing manufacturing services by pharmaceutical and biopharmaceutical companies.
The United States dominates the North American market and is anticipated to maintain this position in the forecast period. Factors contributing to this market dominance include a rising demand for clinical trials, the continuous growth of the pharmaceutical and medical device industries, increasing healthcare expenditure, substantial investment in research and development (R&D), and the presence of key market players that offer comprehensive services encompassing manufacturing, storage, logistics, and more. Notable organizations such as Alderley Analytical and Almac provide a wide range of integrated services to over 600 pharmaceutical and biotech companies, further bolstering the market's growth in the country. Additionally, the substantial presence and significant impact of biopharmaceutical companies in the region, in terms of revenue, technological advancements, and employment opportunities, are expected to contribute to the market's expansion in this area.
Competitive Landscape of Biotechnology Contract Manufacturing Market
The biotechnology contract manufacturing (CMO) market is a highly competitive market, with a number of global and regional players vying for market share. The key players in the biotechnology CMO market include Lonza, Thermo Fisher Scientific, Wuxi AppTec, Catalent and others. These companies offer a range of biotechnology CMO services, including drug substance manufacturing, drug product manufacturing, fill-finish, and packaging. They also compete on the basis of factors such as price, capacity, expertise, and geographic reach.
The biotechnology CMO market is expected to grow significantly in the coming years, driven by factors such as the increasing development of biologics and other complex therapies, the rising demand for outsourcing of manufacturing activities, and the growing focus on personalized medicine. This growth is likely to attract new entrants into the market, further intensifying competition. Biotechnology CMOs are investing heavily in research and development to develop new and improved manufacturing processes and technologies. This is helping them to reduce costs, improve quality, and shorten time-to-market for new products. The biotechnology CMO market is becoming increasingly consolidated, with the major players acquiring smaller companies to expand their capacity and expertise. This is leading to fewer players in the market, but also to larger and more integrated CMOs.
Emerging markets, such as China and India, are becoming increasingly important for the biotechnology CMO market. CMOs are expanding their operations in these markets to capitalize on the growing demand for their services. Overall, the biotechnology CMO market is a highly competitive market and is expected to remain so in the coming years. CMOs are focusing on innovation, consolidation, and expansion into emerging markets to maintain their competitive edge. The competitive landscape of the biotechnology CMO market is also being shaped by the growing adoption of digital technologies, such as artificial intelligence (AI) and machine learning (ML). These technologies are being used to improve the efficiency and quality of manufacturing processes.
Recent Developments
Discover exceptional experiences through testimonials from our satisfied customers.
"As for the experience of using your service, I overall enjoyed the interactions and the report. I thought your report reflects well the overall market trends and the key players.Your data on China, understandably, was partial at best, given the status of the industry and the regulatory compliance in China."
"Delighted with the affordable, in-depth report! Instant replies to queries made the project smooth. Met client expectations seamlessly with the invaluable insights provided. Highly recommend for quality and efficiency!"
